ResearcherUniversity of Mississippi Medical CenterActive in the last 2 years
Yin‐Yuan Mo
Matched on ORCID iD 0000-0002-4980-0186; OpenAlex author ID A5074668225, A5111622113. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 13
2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper
Papers 5
- Corrigendum to "N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis" [Genes & Diseases 10 (2023) 554-567]. Last author DOI 10.1016/j.gendis.2024.101352↗
- N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis. Last author DOI 10.1016/j.gendis.2022.02.014↗
- LINC00346 promotes pancreatic cancer progression through the CTCF-mediated Myc transcription. Last author DOI 10.1038/s41388-019-0918-z↗
- MeCP2 suppresses LIN28A expression via binding to its methylated-CpG islands in pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.7507↗
- Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model. Co-author DOI 10.18632/oncotarget.5641↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Wan‐Xin Peng · 4 shared papers, 2016–2024 · strength 0.62
- Paper Corrigendum to "N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis" … DOI 10.1016/j.gendis.2024.101352↗
- Paper N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis. DOI 10.1016/j.gendis.2022.02.014↗
- Paper LINC00346 promotes pancreatic cancer progression through the CTCF-mediated Myc transcription. DOI 10.1038/s41388-019-0918-z↗
- Jiahong Jiang · 2 shared papers, 2023–2024 · strength 0.45
- Paper Corrigendum to "N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis" … DOI 10.1016/j.gendis.2024.101352↗
- Paper N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis. DOI 10.1016/j.gendis.2022.02.014↗
- Liu Yang · 2 shared papers, 2019–2023 · strength 0.33
- Youli Zhang · 1 shared paper, 2016 · strength 0.05
- Aihua Gong · 1 shared paper, 2016 · strength 0.05
- Min Xu · 1 shared paper, 2016 · strength 0.05
- Lu Ge · 1 shared paper, 2016 · strength 0.05
- Lynette M. Smith · 1 shared paper, 2015 · strength 0.05
- Priya Pai · 1 shared paper, 2015 · strength 0.05
- Parama Dey · 1 shared paper, 2015 · strength 0.05
- Muzafar Ahmad Macha · 1 shared paper, 2015 · strength 0.05
- Surinder K. Batra · 1 shared paper, 2015 · strength 0.05
- Satyanarayana Rachagani · 1 shared paper, 2015 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.